HNSCC
MCID: SQM013
MIFTS: 75

Squamous Cell Carcinoma, Head and Neck (HNSCC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

MalaCards integrated aliases for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 57 13
Squamous Cell Carcinoma of the Head and Neck 12 20 43 72 29 6 15 70
Head and Neck Squamous Cell Carcinoma 12 20 43 15 17
Hnscc 57 20 43 72 54
Head and Neck Cancer 20 36 6 42
Carcinoma, Squamous Cell of Head and Neck 73 20
Squamous Cell Carcinoma of the Nasal Cavity and Paranasal Sinuses 58
Squamous Cell Carcinoma of the Nasal Cavity and Sinuses 58
Squamous Cell Carcinoma, Head and Neck, Somatic 57
Squamous Cell Carcinoma of the Hypopharynx 58
Squamous Cell Carcinoma of Salivary Glands 58
Squamous Cell Carcinoma of the Oral Cavity 58
Squamous Cell Carcinomas of Head and Neck 12
Squamous Cell Carcinoma of the Oropharynx 58
Carcinoma, Squamous Cell, Head and Neck 39
Salivary Gland Squamous Cell Carcinoma 17
Squamous Cell Carcinoma of the Larynx 58
Squamous Cell Carcinoma of the Lip 58
Carcinoma of the Head and Neck 12
Squamous Cell Carcinoma of Lip 70
Lip Squamous Cell Carcinoma 54
Cancer of Head and Neck 70
Cancer, Head/neck 39
Scchn 43

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal recessive


HPO:

31
squamous cell carcinoma, head and neck:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:5520
OMIM® 57 275355
KEGG 36 H02420
NCIt 50 C34447
SNOMED-CT 67 716659002
MedGen 41 C1168401
SNOMED-CT via HPO 68 258211005 28899001 402815007
UMLS 70 C0278996 C0280302 C1168401

Summaries for Squamous Cell Carcinoma, Head and Neck

MedlinePlus Genetics : 43 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.HNSCC is classified by its location: it can occur in the mouth (oral cavity), the middle part of the throat near the mouth (oropharynx), the space behind the nose (nasal cavity and paranasal sinuses), the upper part of the throat near the nasal cavity (nasopharynx), the voicebox (larynx), or the lower part of the throat near the larynx (hypopharynx). Depending on the location, the cancer can cause abnormal patches or open sores (ulcers) in the mouth and throat, unusual bleeding or pain in the mouth, sinus congestion that does not clear, sore throat, earache, pain when swallowing or difficulty swallowing, a hoarse voice, difficulty breathing, or enlarged lymph nodes.HNSCC can spread (metastasize) to other parts of the body, such as the lymph nodes or lungs. If it spreads, the cancer has a worse prognosis and can be fatal. About half of affected individuals survive more than five years after diagnosis.

MalaCards based summary : Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to lung cancer and esophageal cancer, and has symptoms including tinnitus, snoring and halitosis. An important gene associated with Squamous Cell Carcinoma, Head and Neck is ING1 (Inhibitor Of Growth Family Member 1), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Acetylcysteine and Titanium dioxide have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, tonsil and lymph node, and related phenotype is squamous cell carcinoma.

Disease Ontology : 12 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

GARD : 20 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. At least 75 % of head and neck cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV-16, is a risk factor for some types of head and neck cancers. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments.

MedlinePlus : 42 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. Most begin in the moist tissues that line the mouth, nose, and throat. Symptoms include A lump or sore that does not heal A sore throat that does not go away Trouble swallowing A change or hoarseness in the voice Head and neck cancers are twice as common in men. Using tobacco or alcohol increases your risk. In fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers. To diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. You will have a biopsy, where a sample of tissue is taken out and examined under a microscope. It is the only test that can tell for sure if you have cancer. If found early, these cancers are often curable. Treatments may include surgery, radiation therapy, chemotherapy, or a combination. Treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. NIH: National Cancer Institute

KEGG : 36 Head and neck cancers are a heterogeneous collection of malignancies of the upper aerodigestive tract, salivary glands and thyroid. The most common type of cancer in the head and neck is squamous cell carcinoma. It mainly originates from the mucosal space, which extends from the skull base to the proximal esophagus. The head and neck region is subdivided in the oral cavity, pharynx and larynx. The pharyngeal space contains the nasopharynx, oropharynx and hypopharynx and includes the tonsils, the floor of the mouth and the soft palate. Although head and neck squamous cell carcinoma (HNSCC) is traditionally associated with smoking and alcohol drinking, a growing proportion of head and neck tumors, mainly of the oropharynx, are associated with human papilloma virus (HPV).

UniProtKB/Swiss-Prot : 72 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Wikipedia : 73 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

More information from OMIM: 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 794)
# Related Disease Score Top Affiliating Genes
1 lung cancer 32.4 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR98 MIR210
2 esophageal cancer 32.3 TP53 PTEN MIR21 MIR205 LUCAT1 HOTAIR
3 melanoma 32.2 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR210 MIR205
4 bladder cancer 32.1 TP53 SPRY4-IT1 PTEN MIR21 MIR205 HOTAIR
5 glioblastoma 31.9 TP53 TNFRSF10B PTEN MIR210 MIR21 HOTAIR
6 small cell cancer of the lung 31.9 TP53 PTEN MIR21 HOTAIR
7 glioma 31.8 TP53 SPRY4-IT1 PTEN MIR210 MIR21 LUCAT1
8 thyroid carcinoma 31.7 PTEN HOTAIR H19 GAS5
9 lung cancer susceptibility 3 31.7 TP53 MIR21 MIR205 HOTAIR H19 GAS5
10 hepatocellular carcinoma 31.7 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR210 MIR21
11 pancreatic cancer 31.6 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR210 MIR21
12 ovarian cancer 31.6 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR210 MIR21
13 renal cell carcinoma, nonpapillary 31.6 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR210 MIR21
14 leukemia, acute myeloid 31.6 TP53 TNFRSF10B PTEN MIR210 MIR21 HOTAIR
15 squamous cell carcinoma 31.6 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR205 ING1
16 osteogenic sarcoma 31.5 TP53 LUCAT1 HOTAIR H19 GAS5
17 retinitis pigmentosa 11 31.5 TP53 PTEN HOTAIR
18 high grade glioma 31.5 TP53 TNFRSF10B SPRY4-IT1 PTEN HOTAIR H19
19 prostate cancer 31.5 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR210 MIR21
20 kidney cancer 31.4 TP53 PTEN MIR210 MIR21 HOTAIR H19
21 breast cancer 31.4 TP53 TNFRSF10B SPRY4-IT1 PTEN MIR98 MIR210
22 neuroblastoma 31.4 TP53 PTEN MIR21 HOTAIR HAND2-AS1 H19
23 gastric cancer 31.4 TP53 SPRY4-IT1 PTEN MIR21 HOTAIR H19
24 endometrial cancer 31.4 TP53 PTEN MIR205 HOTAIR HAND2-AS1 H19
25 oral squamous cell carcinoma 31.4 TP53 MIR21 MIR205 HOTAIR H19
26 cervical cancer 31.4 TP53 SPRY4-IT1 PTEN MIR21 MIR205 HOTAIR
27 clear cell renal cell carcinoma 31.3 TP53 SPRY4-IT1 PTEN MIR210 MIR21 LUCAT1
28 gastric adenocarcinoma 31.3 TP53 PTEN HOTAIR H19
29 laryngeal squamous cell carcinoma 31.1 TP53 PTEN MIR21 HOTAIR H19
30 myeloma, multiple 31.1 TP53 PTEN MIR21 HOTAIR H19 GAS5
31 gastric cardia adenocarcinoma 31.1 HOTAIR H19 EPIST
32 pancreatic ductal adenocarcinoma 31.0 TP53 PTEN MIR210 MIR21 MIR205 HOTAIR
33 bladder urothelial carcinoma 31.0 TP53 PTEN HOTAIR GAS5
34 nasopharyngeal carcinoma 30.9 TP53 PTEN MIR21 HOTAIR H19 GAS5
35 tongue squamous cell carcinoma 30.8 TP53 PTEN MIR21 CYTOR
36 pharynx cancer 30.5 TP53 MIR21 FAM3D-AS1
37 thyroid gland cancer 11.3
38 cheilitis glandularis 11.3
39 salivary gland cancer, adult 11.1
40 oropharynx cancer 11.0
41 neutropenia 11.0
42 merkel cell carcinoma 10.9
43 retinoblastoma 10.8
44 diffuse large b-cell lymphoma 10.8 TP53 PTEN MIR210 MIR21 HOTAIR
45 gastrointestinal system cancer 10.8 MIR210 MIR21 MIR205 HOTAIR H19
46 gallbladder cancer 10.7 TP53 PTEN HOTAIR H19 CYTOR
47 oral cavity cancer 10.7
48 tongue disease 10.7 TP53 PTEN MIR21 CYTOR
49 autonomic nervous system neoplasm 10.7 TP53 PTEN MIR98 MIR21
50 cell type benign neoplasm 10.7 TP53 PTEN MIR210 MIR21

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to Squamous Cell Carcinoma, Head and Neck

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

31
# Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma 31 HP:0002860

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Lab:
beta family transforming growth factor resistance

Clinical features from OMIM®:

275355 (Updated 20-May-2021)

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


tinnitus; snoring; halitosis; sore throat; coughing; vertigo/dizziness; equilibration disorder

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 556)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Titanium dioxide Approved Phase 4 13463-67-7
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Methadone Approved Phase 4 76-99-3 4095
8
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
9
Cevimeline Approved Phase 4 107233-08-9 83898 25137844
10
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
11
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
12
Meperidine Approved Phase 4 57-42-1 4058
13
Citalopram Approved Phase 4 59729-33-8 2771
14
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
15
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
16
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Amifostine Approved, Investigational Phase 4 20537-88-6 2141
20
Dexetimide Withdrawn Phase 4 21888-98-2
21 Antidotes Phase 4
22 Expectorants Phase 4
23 N-monoacetylcystine Phase 4
24 Antidepressive Agents Phase 4
25 Narcotics Phase 4
26 Anesthetics Phase 4
27 Anesthetics, Intravenous Phase 4
28 Anesthetics, General Phase 4
29 Cardiotonic Agents Phase 4
30 Respiratory System Agents Phase 4
31 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
32 Antitussive Agents Phase 4
33 Muscarinic Agonists Phase 4
34 Dopamine Agents Phase 4
35 BB 1101 Phase 4
36 Hemostatics Phase 4
37 Serotonin Uptake Inhibitors Phase 4
38 Cytochrome P-450 Enzyme Inhibitors Phase 4
39 Radiation-Protective Agents Phase 4
40 Mitomycins Phase 4
41
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
42
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
43
Racepinephrine Approved Phase 3 329-65-7 838
44
Amoxicillin Approved, Vet_approved Phase 2, Phase 3 26787-78-0 33613
45
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
46
Histamine Approved, Investigational Phase 2, Phase 3 51-45-6, 75614-87-8 774
47
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
48
Promethazine Approved, Investigational Phase 3 60-87-7 4927
49
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
50
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1

Interventional clinical trials:

(show top 50) (show all 2072)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
2 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
3 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
4 Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy Unknown status NCT02484677 Phase 4 Cisplatin;Docetaxel;5-Fluorouracile
5 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage Unknown status NCT00894153 Phase 4 chemotherapy plus p53;chemotherapy
6 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
7 EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS Unknown status NCT02241876 Phase 4 N-acetylcysteine
8 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
9 Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer Completed NCT00333099 Phase 4
10 An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer Completed NCT00198263 Phase 4
11 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
12 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
13 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
14 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
15 The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements Completed NCT02241083 Phase 4 Dopamine;Norepinephrine
16 Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
17 Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients: A Randomized Clinical Trial Completed NCT02926573 Phase 4 Gabapentin;Placebo
18 A Prospective Randomized Study of LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients Completed NCT02597582 Phase 4
19 Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective Than Fentanyl? Completed NCT01317589 Phase 4 fentanyl;methadone
20 Clinical Evaluation of a Salivary Substitute and a Mucoprotective Product on Xerostomia in Head-and-neck Cancer Patients Completed NCT01316393 Phase 4
21 Prevention of Depression in Patients Being Treated for Head and Neck Cancer Completed NCT00536172 Phase 4 Escitalopram;Placebo
22 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
23 Absorption of Orally Ingested Phosphate in Head and Neck Cancer Patients With and Without Refeeding Syndrome Completed NCT02880072 Phase 4
24 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
25 Does Continuous Popliteal Nerve Block Improve Pain Management for Patients Undergoing Major Maxilla or Mandible Resection With Microvascular Reconstruction Using a Free Fibula Graft Recruiting NCT03607227 Phase 4 Levobupivacaine;Saline Solution
26 A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10). Recruiting NCT04489888 Phase 4 Pembrolizumab;Carboplatin;Paclitaxel
27 A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor Recruiting NCT04766827 Phase 4 albumin-bound paclitaxel
28 Study on the Treatment of Refractory and Locally Advanced Head and Neck Malignant Tumor With Anlotinib Hydrochloride Capsules Combined With Chemoradiotherapy Recruiting NCT04507035 Phase 4 Anlotinib hydrochloride capsules
29 Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT04204382 Phase 4 Levofloxacin Injection;Compound Kushen Injection(CKI)
30 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Suspended NCT01288625 Phase 4 Amifostine
31 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
32 Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial Withdrawn NCT03714867 Phase 4 Pregabalin 150mg
33 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
34 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
35 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
36 the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial Unknown status NCT00603759 Phase 3 celecoxib;placebo
37 Randomised Phase-III-trial of Simultaneous Radiochemotherapy (RCT) of Locally Advanced Head and Neck Cancer in the Stages III and IV A-B: Comparing Dose Reduced Radiotherapy (63,6 Gy) With Paclitaxel/Cisplatin to Standard Radiotherapy (70,2 Gy) With 5-Fluorouracil/Cisplatin Unknown status NCT01126216 Phase 3 Paclitaxel/Cisplatin;5-FU/Cisplatin
38 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck. Unknown status NCT02661152 Phase 3 Nimorazole
39 Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
40 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
41 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
42 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
43 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
44 Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma Unknown status NCT01124409 Phase 3
45 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
46 Efficacy and Cost Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Locally Advanced Head and Neck Cancer to Prevent Aspiration Pneumonia. A Randomized Phase II-III Study Unknown status NCT01598402 Phase 2, Phase 3 amoxicillin/clavulanic acid suspension
47 A Multicenter Randomized Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Parotid Tumors Unknown status NCT01216800 Phase 3
48 Towards a Pain Free Hospital: Effect and Cost Effectiveness of Routine Screening and Treatment for Pain in Head and Neck Oncology Outpatients Unknown status NCT01716780 Phase 3
49 The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial Unknown status NCT02282839 Phase 3
50 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck 29 ING1 TNFRSF10B

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

40
Salivary Gland, Tonsil, Lymph Node, Thyroid, Skin, Tongue, Lung

Publications for Squamous Cell Carcinoma, Head and Neck

Articles related to Squamous Cell Carcinoma, Head and Neck:

(show top 50) (show all 4642)
# Title Authors PMID Year
1
Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. 57 6
11801303 2002
2
Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. 6 57
10866301 2000
3
Rare loss-of-function mutation of a death receptor gene in head and neck cancer. 57 6
9721851 1998
4
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. 6 54
20415598 2010
5
Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling. 57
32165588 2020
6
Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer. 6
30816478 2019
7
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
8
Comprehensive genomic characterization of head and neck squamous cell carcinomas. 57
25631445 2015
9
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
10
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. 57
21798897 2011
11
The mutational landscape of head and neck squamous cell carcinoma. 57
21798893 2011
12
Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. 6
21531084 2011
13
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. 61 47
20369013 2010
14
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. 57
19776030 2009
15
An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. 57
15640797 2005
16
Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. 57
15317812 2004
17
Functional evidence for a squamous cell carcinoma mortality gene(s) on human chromosome 4. 57
12140764 2002
18
Microsatellite alterations in serum DNA of head and neck cancer patients. 57
8782464 1996
19
Resistance of human squamous carcinoma cells to transforming growth factor beta 1 is a recessive trait. 57
8327510 1993
20
Telephone triage of suspected head and neck cancer patients during the coronavirus disease 2019 pandemic using the Head and Neck Cancer Risk Calculator version 2. 42
33648611 2021
21
Sentinel lymph node biopsy in head and neck cutaneous melanomas: A PRISMA-compliant systematic review and meta-analysis. 42
33592872 2021
22
Using arterial spin labeling blood flow and its histogram analysis to distinguish early-stage nasopharyngeal carcinoma from lymphoid hyperplasia. 42
33663135 2021
23
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. 54 61
20406834 2010
24
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. 47
19782034 2009
25
MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. 47
19351747 2009
26
Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. 54 61
19240170 2009
27
Genetic polymorphisms in DNA base excision repair gene XRCC1 and the risk of squamous cell carcinoma of the head and neck. 61 54
19284666 2009
28
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. 47
19179615 2009
29
MicroRNA alterations in head and neck squamous cell carcinoma. 47
18798260 2008
30
Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205. 47
19043531 2008
31
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. 54 61
18997665 2008
32
Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. 61 54
18528899 2008
33
A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. 61 54
18413827 2008
34
STAT3 signaling is induced by intercellular adhesion in squamous cell carcinoma cells. 61 54
17961551 2008
35
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. 54 61
18223210 2008
36
The role of genetic factor in etiopathogenesis of squamous cell carcinoma of the head and neck in young adults. 61 54
17653748 2007
37
P53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. 54 61
17970074 2007
38
MicroRNA expression profiles in head and neck cancer cell lines. 47
17475218 2007
39
Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. 61 54
17426250 2007
40
EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. 54 61
17224267 2007
41
Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. 61 54
17317828 2007
42
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. 47
17222355 2007
43
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. 54 61
16615113 2006
44
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. 54 61
16618910 2006
45
Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. 61 54
16302191 2006
46
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. 54 61
16551875 2006
47
SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. 54 61
16007169 2005
48
A study of TRAIL receptors in squamous cell carcinoma of the head and neck. 54 61
15897419 2005
49
The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck. 61 54
15781759 2005
50
Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck. 61 54
15608417 2005

Variations for Squamous Cell Carcinoma, Head and Neck

ClinVar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

6 (show top 50) (show all 396)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TNFRSF10B TNFRSF10B, 2-BP INS Insertion Pathogenic 6194 GRCh37:
GRCh38:
2 PTEN NM_001304718.2(PTEN):c.-389C>G SNV Pathogenic 7842 rs121909237 GRCh37: 10:89692878-89692878
GRCh38: 10:87933121-87933121
3 ING1 NM_198219.3(ING1):c.644G>C (p.Cys215Ser) SNV Pathogenic 8067 rs121909250 GRCh37: 13:111372083-111372083
GRCh38: 13:110719736-110719736
4 ING1 NM_198219.3(ING1):c.647A>G (p.Asn216Ser) SNV Pathogenic 8068 rs121909251 GRCh37: 13:111372086-111372086
GRCh38: 13:110719739-110719739
5 ING1 NM_198219.3(ING1):c.575C>A (p.Ala192Asp) SNV Pathogenic 8069 rs121909252 GRCh37: 13:111372014-111372014
GRCh38: 13:110719667-110719667
6 TP53 NM_000546.5(TP53):c.578A>G (p.His193Arg) SNV Pathogenic 184979 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
7 TP53 NM_000546.6(TP53):c.422G>T SNV Pathogenic 376568 rs587781288 GRCh37: 17:7578508-7578508
GRCh38: 17:7675190-7675190
8 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Pathogenic 12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
9 TP53 NM_000546.5(TP53):c.713dup (p.Cys238fs) Duplication Pathogenic 803307 rs1597365075 GRCh37: 17:7577567-7577568
GRCh38: 17:7674249-7674250
10 TP53 NM_000546.6(TP53):c.383delC Deletion Pathogenic 659670 rs1597371666 GRCh37: 17:7578547-7578547
GRCh38: 17:7675229-7675229
11 TP53 NM_000546.5(TP53):c.493C>T (p.Gln165Ter) SNV Pathogenic 182930 rs730882001 GRCh37: 17:7578437-7578437
GRCh38: 17:7675119-7675119
12 TP53 NM_000546.6(TP53):c.637C>T (p.Arg213Ter) SNV Pathogenic 43590 rs397516436 GRCh37: 17:7578212-7578212
GRCh38: 17:7674894-7674894
13 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic 12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
14 TP53 NM_000546.6(TP53):c.646G>C SNV Pathogenic 406596 rs730882025 GRCh37: 17:7578203-7578203
GRCh38: 17:7674885-7674885
15 TP53 NM_000546.6(TP53):c.747G>T SNV Pathogenic 12352 rs28934571 GRCh37: 17:7577534-7577534
GRCh38: 17:7674216-7674216
16 TNFRSF10B NM_003842.5(TNFRSF10B):c.598del (p.Ser200fs) Deletion Pathogenic 1027775 GRCh37: 8:22885994-22885994
GRCh38: 8:23028481-23028481
17 TNFRSF10B NM_003842.5(TNFRSF10B):c.748+1G>A SNV Pathogenic 1032474 GRCh37: 8:22885843-22885843
GRCh38: 8:23028330-23028330
18 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
19 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Pathogenic 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
20 TP53 NM_000546.6(TP53):c.1010G>A (p.Arg337His) SNV Pathogenic 12379 rs121912664 GRCh37: 17:7574017-7574017
GRCh38: 17:7670699-7670699
21 TP53 NM_000546.6(TP53):c.455C>T (p.Pro152Leu) SNV Pathogenic 142766 rs587782705 GRCh37: 17:7578475-7578475
GRCh38: 17:7675157-7675157
22 EGFR-AS1 , EGFR NM_005228.5(EGFR):c.2327G>A (p.Arg776His) SNV drug response 126515 rs483352806 GRCh37: 7:55249029-55249029
GRCh38: 7:55181336-55181336
23 EGFR NM_005228.5(EGFR):c.2155G>C (p.Gly719Arg) SNV drug response 45224 rs28929495 GRCh37: 7:55241707-55241707
GRCh38: 7:55174014-55174014
24 GNAS NM_000516.6(GNAS):c.602G>A (p.Arg201His) SNV Likely pathogenic 15934 rs121913495 GRCh37: 20:57484421-57484421
GRCh38: 20:58909366-58909366
25 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely pathogenic 12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
26 GNAS NM_000516.6(GNAS):c.601C>T (p.Arg201Cys) SNV Likely pathogenic 15933 rs11554273 GRCh37: 20:57484420-57484420
GRCh38: 20:58909365-58909365
27 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg) SNV Likely pathogenic 45466 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
28 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
29 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln) SNV Likely pathogenic 7829 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
30 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely pathogenic 95047 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
31 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Likely pathogenic 16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
32 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
33 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
34 HRAS , LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Likely pathogenic 12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
35 GNAS NM_000516.6(GNAS):c.602G>T (p.Arg201Leu) SNV Likely pathogenic 210045 rs121913495 GRCh37: 20:57484421-57484421
GRCh38: 20:58909366-58909366
36 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met) SNV Likely pathogenic 233951 rs876660754 GRCh37: 17:7578413-7578413
GRCh38: 17:7675095-7675095
37 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu) SNV Likely pathogenic 13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
38 HRAS , LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely pathogenic 12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
39 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Likely pathogenic 12370 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
40 BRAF NM_004333.6(BRAF):c.1780G>C (p.Asp594His) SNV Likely pathogenic 375947 rs397516896 GRCh37: 7:140453155-140453155
GRCh38: 7:140753355-140753355
41 TP53 NM_000546.5(TP53):c.394A>G (p.Lys132Glu) SNV Likely pathogenic 376626 rs747342068 GRCh37: 17:7578536-7578536
GRCh38: 17:7675218-7675218
42 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro) SNV Likely pathogenic 376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
43 CTNNB1 NM_001904.4(CTNNB1):c.101G>T (p.Gly34Val) SNV Likely pathogenic 17582 rs28931589 GRCh37: 3:41266104-41266104
GRCh38: 3:41224613-41224613
44 TP53 NM_000546.5(TP53):c.374C>T (p.Thr125Met) SNV Likely pathogenic 183748 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
45 CTNNB1 NM_001904.4(CTNNB1):c.100G>C (p.Gly34Arg) SNV Likely pathogenic 376233 rs121913399 GRCh37: 3:41266103-41266103
GRCh38: 3:41224612-41224612
46 CTNNB1 NM_001904.4(CTNNB1):c.101G>C (p.Gly34Ala) SNV Likely pathogenic 376390 rs28931589 GRCh37: 3:41266104-41266104
GRCh38: 3:41224613-41224613
47 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro) SNV Likely pathogenic 231214 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
48 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely pathogenic 135359 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
49 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro) SNV Likely pathogenic 231060 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
50 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

72
# Symbol AA change Variation ID SNP ID
1 ING1 p.Ala335Asp VAR_017420
2 ING1 p.Cys358Ser VAR_017421
3 ING1 p.Asn359Ser VAR_017422
4 ING3 p.Asp20Gly VAR_021263
5 PTEN p.Ala121Gly VAR_018103 rs121909237

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

9 (show top 50) (show all 17362)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 12
2 COSM133256111 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1040C>T p.S347F 9:99146601-99146601 12
3 COSM97906895 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1016C>T p.S339F 9:99146601-99146601 12
4 COSM135128838 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1259C>T p.S420F 9:99146601-99146601 12
5 COSM97922732 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 12
6 COSM84678061 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 12
7 COSM98728167 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 12
8 COSM107058787 RARA skin,neck,carcinoma,squamous cell carcinoma c.1093C>T p.P365S 17:40356221-40356221 12
9 COSM98724263 RARA skin,neck,carcinoma,squamous cell carcinoma c.1432C>T p.P478S 17:40356221-40356221 12
10 COSM86828717 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 12
11 COSM98707797 RARA skin,neck,carcinoma,squamous cell carcinoma c.1369C>T p.P457S 17:40356221-40356221 12
12 COSM94496058 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 12
13 COSM133940534 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 12
14 COSM107373333 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 12
15 COSM130526023 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 12
16 COSM96948694 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
17 COSM97161923 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
18 COSM96619514 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
19 COSM97161935 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
20 COSM144156675 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.473G>A p.G158E 20:42352227-42352227 12
21 COSM96619533 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
22 COSM93273665 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
23 COSM96721565 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
24 COSM96835332 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
25 COSM142597931 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.454C>T p.S152L 20:42352239-42352239 12
26 COSM144156682 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.461C>T p.S154L 20:42352239-42352239 12
27 COSM97061657 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
28 COSM96835350 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
29 COSM96721578 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
30 COSM96948708 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
31 COSM93273656 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
32 COSM97061670 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
33 COSM142597920 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.466G>A p.G156E 20:42352227-42352227 12
34 COSM101904169 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 12
35 COSM92948518 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 12
36 COSM132595830 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1243C>T p.P415S 9:8518130-8518130 12
37 COSM132601883 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1718G>A p.S573N 9:8504347-8504347 12
38 COSM132313437 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 12
39 COSM102248340 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1706G>A p.S569N 9:8504347-8504347 12
40 COSM102241575 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1231C>T p.P411S 9:8518130-8518130 12
41 COSM92952483 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 12
42 COSM102146055 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.3818C>T p.S1273F 9:8341168-8341168 12
43 COSM117943076 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 12
44 COSM102142838 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1252C>T p.P418S 9:8518130-8518130 12
45 COSM117937918 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 12
46 COSM117940165 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.3827C>T p.S1276F 9:8341168-8341168 12
47 COSM101917565 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 12
48 COSM132320384 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 12
49 COSM101909541 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 12
50 COSM91022846 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 12

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

7 (show all 42)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 33952 1 50700000 61300000 Amplification head and neck squamous cell carcinoma
2 71135 12 67700000 71500000 Amplification head and neck squamous cell carcinoma
3 78639 13 55300000 73300000 Amplification head and neck squamous cell carcinoma
4 90904 15 25700000 28100000 Amplification head and neck squamous cell carcinoma
5 93784 15 59100000 59300000 Copy number MET head and neck squamous cell carcinoma
6 118006 17 7505821 7531588 LOH TP53 head and neck squamous cell carcinoma
7 119192 18 1 7100000 Amplification head and neck squamous cell carcinoma
8 119790 18 17200000 19000000 Amplification head and neck squamous cell carcinoma
9 166134 3 1 87900000 Loss head and neck squamous cell carcinoma
10 167635 3 121900000 167600000 Gain head and neck squamous cell carcinoma
11 169556 3 142800000 148900000 Amplification head and neck squamous cell carcinoma
12 171486 3 168801287 168851758 Amplification MECOM head and neck squamous cell carcinoma
13 171495 3 168867391 169381563 Amplification MECOM head and neck squamous cell carcinoma
14 172487 3 182700000 187900000 Amplification RFC4 head and neck squamous cell carcinoma
15 174746 12 7773277 7793336 Deletion CLEC4C head and neck squamous cell carcinoma
16 179443 3 91000000 121900000 Gain head and neck squamous cell carcinoma
17 179973 4 1 50400000 Loss head and neck squamous cell carcinoma
18 204736 6 114600000 171115067 Gain head and neck squamous cell carcinoma
19 217049 7 1 159138663 Copy number head and neck squamous cell carcinoma
20 225369 7 45400000 54000000 Gain EGFR head and neck squamous cell carcinoma
21 225383 7 45400000 54000000 Amplification EGFR head and neck squamous cell carcinoma
22 225403 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
23 225404 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
24 225408 7 45400000 54000000 Deletion or amplification EGFR head and neck squamous cell carcinoma
25 225413 7 45400000 58000000 Amplification head and neck squamous cell carcinoma
26 226532 7 58000000 59900000 Amplification head and neck squamous cell carcinoma
27 232747 8 119200000 122500000 Gain MYC head and neck squamous cell carcinoma
28 233769 8 127300000 139900000 Gain KHDRBS3 head and neck squamous cell carcinoma
29 234876 8 139900000 146364022 Gain PTK2 head and neck squamous cell carcinoma
30 234895 8 139900000 146364022 Gain PTP4A3 head and neck squamous cell carcinoma
31 238011 8 28800000 45600000 Amplification head and neck squamous cell carcinoma
32 239988 8 43100000 45600000 Amplification head and neck squamous cell carcinoma
33 240109 8 45600000 146364022 Gain GPAA1 head and neck squamous cell carcinoma
34 241899 8 68000000 70500000 Amplification head and neck squamous cell carcinoma
35 243677 8 86900000 101600000 Amplification RUNX1T1 head and neck squamous cell carcinoma
36 249984 9 19900000 25500000 Deletion CDKN2A head and neck squamous cell carcinoma
37 300518 11 95351087 95715992 Methylation MAML2 head and neck squamous cell carcinoma
38 300530 12 123374913 123617963 Methylation NCOR2 head and neck squamous cell carcinoma
39 300892 14 72672931 72756862 Methylation PSEN1 head and neck squamous cell carcinoma
40 300893 14 72811670 72995039 Methylation NUMB head and neck squamous cell carcinoma
41 302931 19 45863651 45888396 Methylation NUMBL head and neck squamous cell carcinoma
42 303261 20 10566331 10602694 Methylation JAG1 head and neck squamous cell carcinoma

Expression for Squamous Cell Carcinoma, Head and Neck

LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Head Mesenchyme + 5.25 0.000
2 TMPRSS11B transmembrane serine protease 11B Head Mesenchyme - 4.81 0.000
3 CRISP3 cysteine rich secretory protein 3 Head Mesenchyme - 4.48 0.000
4 MAL mal, T cell differentiation protein Head Mesenchyme - 4.39 0.000
5 INHBA inhibin subunit beta A Head Mesenchyme + 4.13 0.000
6 CRNN cornulin Head Mesenchyme - 4.00 0.000
7 KRT17 keratin 17 Head Mesenchyme + 3.94 0.000
8 KRT4 keratin 4 Head Mesenchyme - 3.41 0.000
9 PTHLH parathyroid hormone like hormone Head Mesenchyme + 3.36 0.000
10 CTHRC1 collagen triple helix repeat containing 1 Head Mesenchyme + 3.32 0.000
11 CLCA4 chloride channel accessory 4 Head Mesenchyme - 3.31 0.000
12 WDR72 WD repeat domain 72 Head Mesenchyme + 3.23 0.000
13 MMP10 matrix metallopeptidase 10 Head Mesenchyme + 3.14 0.001
14 TGM3 transglutaminase 3 Head Mesenchyme - 3.08 0.000
15 GBP1 guanylate binding protein 1 Head Mesenchyme + 3.06 0.000
Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for Squamous Cell Carcinoma, Head and Neck

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.63 TP53 TNFRSF10B PTEN MIR210
2 11.51 TP53 PTEN MIR210 MIR21 MIR205
3 11.46 TP53 PTEN ING1
4 10.23 TP53 HOTAIR

GO Terms for Squamous Cell Carcinoma, Head and Neck

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.8 H19 MIR205 MIR21 MIR210 MIR98
2 negative regulation of cell proliferation GO:0008285 9.72 ING1 MIR21 MIR98 PTEN TP53
3 positive regulation of apoptotic process GO:0043065 9.55 PTEN TNFRSF10B TP53 ING3 MIR21
4 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.46 PTEN TP53
5 regulation of protein kinase B signaling GO:0051896 9.43 MIR21 PTEN
6 positive regulation of metalloendopeptidase activity GO:1904685 9.37 MIR205 MIR21
7 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.26 MIR21 MIR210
8 negative regulation of superoxide dismutase activity GO:1901670 8.96 H19 MIR21
9 miRNA mediated inhibition of translation GO:0035278 8.92 MIR205 MIR21 MIR210 MIR98

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.26 MIR98 MIR210 MIR21 MIR205
2 mRNA 3'-UTR binding GO:0003730 8.92 TP53 MIR98 MIR21 MIR205

Sources for Squamous Cell Carcinoma, Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....